Most of the attention around tesamorelin sits below the neck: visceral fat, waist circumference, liver fat. But a second storyline has been running quietly for more than a decade — the idea that a GHRH analogue might sharpen thinking in older adults. That thread produced one genuinely interesting randomised trial in 2012, then went almost silent. In 2025 it was picked up again, in a different population, and the result was far less flattering. If you're searching tesamorelin research because you've seen "brain fog" or "cognitive benefit" in a product description, this is the evidence trail you're actually standing on.

Our compound page sits at /peptides/tesamorelin, and the wider library is at /peptides.

What is tesamorelin, and why would it touch cognition at all?

Tesamorelin is a stabilised analogue of growth hormone-releasing hormone (GHRH). It doesn't supply growth hormone; it prompts the pituitary to release its own in a pulsatile pattern, which in turn raises IGF-1. That's the mechanism behind its only approved use — reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, approved by the US FDA in 2010 as Egrifta.

The cognitive hypothesis comes from a different direction. GH and IGF-1 both decline with age, both cross into or act on the central nervous system, and GHRH receptors are present in brain tissue. Restoring a more youthful GH/IGF-1 rhythm, the argument went, might restore some of the executive function that fades alongside it. It is a plausible hypothesis. Plausible is not the same as demonstrated.

The 2012 trial: a real signal, in a real randomised design

The strongest human evidence is still Baker and colleagues, published in Archives of Neurology in 2012. It was a proper double-blind, placebo-controlled study: 152 adults aged 55–87 randomised, 137 completing, self-injecting tesamorelin 1 mg or placebo subcutaneously 30 minutes before bed for 20 weeks. Roughly half the cohort were cognitively healthy; the rest met criteria for amnestic mild cognitive impairment (MCI).

The findings were genuinely positive, and narrow. Tesamorelin improved measures of executive function — response inhibition on the Stroop task, set-shifting on task-switching tests — in both the healthy and MCI groups. Verbal memory improved modestly, and more so in the MCI group. IGF-1 rose substantially, into the range of a young adult.

What it did not move matters just as much: global cognitive status (MMSE), visual memory, word fluency in some analyses, and processing speed were unchanged. This was a 20-week signal on a handful of computerised executive tasks, not a dementia treatment result. No disease-modifying claim was made, and no phase 3 cognition programme followed.

The replication gap

Fourteen years on, that trial has not been repeated in the same population with the same design. When a single well-run study sits alone for that long, the honest read is "promising and unconfirmed", not "proven". Anyone quoting the 2012 executive-function result as settled is quoting a study of 137 completers.

The 2025 trial: waistline moved, cognition didn't separate

The next serious attempt appeared in The Journal of Infectious Diseases in 2025 — a phase 2 trial in people with HIV, virally suppressed, with abdominal obesity and neurocognitive impairment. The logic was tidy: abdominal obesity is associated with inflammation and worse cognition in this group, tesamorelin reliably shrinks visceral fat, so shrinking it might help cognition.

It didn't, at least not measurably. Of 197 people screened, 73 were randomised 3:2 to tesamorelin or standard of care, and enrolment was stopped early for slow accrual with data monitoring committee approval. After six months:

  • Waist circumference fell more in the tesamorelin arm (median difference −2.7 cm, P = .015) — the compound did what it's approved to do.
  • Neurocognitive performance showed a within-group trend in the tesamorelin arm (mean change 0.146, 95% CI −0.002 to 0.294, P = .060).
  • Between groups, there was no significant difference (P = .673).

The authors' conclusion was appropriately flat: no clear benefit of short-term abdominal fat reduction with tesamorelin on neurocognitive impairment.

Why "within-group improvement" is the trap

That 0.146 figure is exactly the kind of number that gets lifted out of context. A within-group change means the treated participants scored better than they did at baseline. It does not tell you the drug caused it. Repeat neurocognitive testing produces practice effects; this trial was open-label with no placebo arm, so expectation effects were entirely unblinded; and the study was underpowered after stopping early. The comparison that carries the causal weight is the between-group one, and it came back at P = .673.

Read together, the picture is: one blinded trial in older adults with a narrow executive-function signal, and one small open-label trial in people with HIV that found nothing separating the arms. That is a hypothesis in need of a proper replication, not a use case.

Is tesamorelin legal in Australia? The regulatory picture

Tesamorelin is not on the Australian Register of Therapeutic Goods (ARTG) — there is no TGA-approved tesamorelin product in Australia for any indication, cognitive or otherwise. Access, where it happens legitimately, runs through prescriber-controlled unapproved-goods pathways such as the Special Access Scheme or Authorised Prescriber arrangements, at a doctor's discretion and responsibility. Material sold online as "research-only" sits outside that framework entirely, with no assurance of identity, purity or sterility.

Internationally the status is narrower than the marketing suggests. FDA approval since 2010 covers HIV-associated lipodystrophy only. The European application was withdrawn before approval in 2012, so tesamorelin has never been EMA-approved. In the US, the newer F8 formulation (marketed as Egrifta WR) was approved as a lower-volume, weekly-reconstitution version — a convenience change for the same approved indication, not an expansion into cognition or general body composition.

For athletes: GHRH and its analogues, tesamorelin explicitly included, are prohibited at all times under section S2 of the WADA Prohibited List. Any Australian competing under a WADA-code sport should treat this as a hard stop.

One safety note that gets skipped in the cognitive discussion: the US label carries warnings about glucose intolerance and diabetes, because stimulating the GH axis can worsen glycaemic control. That's a real trade-off to weigh against an unreplicated executive-function signal.

The practical read

If you're evaluating tesamorelin, evaluate it on what the evidence supports: visceral fat reduction in a specific approved population, with a metabolic monitoring requirement attached. The cognition story is one 2012 randomised trial with a narrow positive result and one 2025 trial that failed to separate from control. Both deserve to be cited accurately — including by people selling the idea.

Want the next evidence update on tesamorelin and the wider peptide space? Join the free list.

FAQ

Does tesamorelin improve memory or brain fog?

There is no reliable evidence that it does. A 2012 randomised, placebo-controlled trial in 137 completers aged 55–87 found improvements in executive function and modest verbal memory gains over 20 weeks, but that result has not been replicated, and a 2025 trial in people with HIV found no significant between-group cognitive difference.

What did the 2025 tesamorelin cognition trial find?

Published in The Journal of Infectious Diseases, the phase 2 trial randomised 73 people with HIV and abdominal obesity. Waist circumference fell more with tesamorelin (−2.7 cm, P = .015), but neurocognitive performance did not differ significantly between groups (P = .673).

Is tesamorelin legal in Australia?

Tesamorelin is not on the ARTG, so there is no TGA-approved product in Australia. Any legitimate access is through prescriber-controlled unapproved-goods pathways such as the Special Access Scheme; "research-only" online supply sits outside that system.

Is tesamorelin banned in sport?

Yes. GHRH and its analogues, including tesamorelin, are prohibited at all times under section S2 of the WADA Prohibited List, which applies to Australian athletes competing under the WADA code.

Sources

This article is independent information, not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, was never approved by the EMA, and is not on the ARTG in Australia; discuss any treatment decision with a qualified clinician.